A controlled clinical and immunological evaluation of immunotherapy with Bacillus Calmette--Guerin in patients with metastatic cancer.
One hundred thirty adult patients with metastatic solid tumors were studied to evaluate the therapeutic results, toxicity, and immunological effects of three BCG preparations given intradermally by the multiple puncture time technique on either a monthly or weekly schedule: Tice lyophilized BCG, Pasteur lyophilized BCG, and Pasteur fresh-frozen BCG. Patients were randomly assigned in a double-blind manner to receive one of the BCG preparations or saline placebo administered in an identical manner. A battery of immunological tests were performed pretreatment and serially during the investigation. None of the 82 patients with measurable indicator lesions experienced an objective tumor response, nor were there any differences in survival among patients receiving any of the BCG preparations compared to placebo. Toxicity consisted of mild to moderate local cutaneous reactions and liver function abnormalities in BCG-treated patients with no significant differences between BCG preparations. Improvements in each of the assays of immune function performed occurred with roughly equal frequency among patients receiving BCG or placebo. It was not possible to demonstrate any significant clinical or immunological benefit from BCG administration in this patient population with the methodology employed.
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012882:Skin Tests
D001500:BCG Vaccine